Guggenheim Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $52.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price trimmed by Guggenheim from $64.00 to $52.00 in a research note published on Monday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on RARE. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Truist Financial decreased their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Barclays lowered their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Robert W. Baird cut their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Finally, Wells Fargo & Company reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.29.

Ultragenyx Pharmaceutical Trading Up 7.4%

Shares of RARE opened at $24.20 on Monday. Ultragenyx Pharmaceutical has a 52 week low of $18.41 and a 52 week high of $46.50. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -4.07 and a beta of 0.15. The stock has a 50 day moving average of $32.12 and a 200-day moving average of $31.46.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The firm had revenue of $159.93 million for the quarter, compared to the consensus estimate of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The business’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.40) earnings per share. On average, sell-side analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the sale, the chief financial officer directly owned 95,146 shares in the company, valued at $3,461,411.48. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 11,108 shares of company stock valued at $365,262. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Covestor Ltd lifted its holdings in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. Huntington National Bank raised its position in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Ultragenyx Pharmaceutical by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after buying an additional 404 shares in the last quarter. Xponance Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 406 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical by 2.3% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 434 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: CEO Emil D. Kakkis will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, increasing senior-management visibility and providing a live/replay channel for investors to hear program updates and commercialization progress. Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference
• Positive Sentiment: HC Wainwright revised several near-term EPS estimates upward and raised its FY2026 outlook (and maintains a “Buy” rating with a $60 price target), signaling analyst confidence in Ultragenyx’s longer-term revenue profile and helping sentiment. HC Wainwright analyst note (MarketBeat summary)
• Neutral Sentiment: Institutional activity is mixed but notable: large additions from some funds (e.g., FMR materially increased exposure) while others trimmed positions, which can amplify intraday moves but doesn’t single-handedly direct the trend. Quiver / institutional holdings summary
• Negative Sentiment: Guggenheim cut its price target to $52, which can weigh on upside expectations and headline-driven sentiment even if other analysts remain more bullish. Guggenheim Lowers Ultragenyx Price Target to $52
• Negative Sentiment: Reports pointing to a clinical setback have surfaced, raising execution and development risk for pipeline programs; such headlines typically pressure biotech names until details or remediation plans are clear. Ultragenyx Faces Mounting Challenges After Clinical Setback
• Negative Sentiment: An investor alert from Pomerantz LLP signals an active investigation into potential claims by Ultragenyx investors, adding legal/settlement risk and potential headline volatility. Pomerantz Investigates Claims on Behalf of Ultragenyx Investors

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.